Associated Papers
NOTCH1-Related Leukoencephalopathy: A Novel Variant and Literature Review.
Della Vecchia S et al.
International Journal of Molecular Sciences, 2024
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I et al.
Journal of Hematology & Oncology, 2021
34167562 (PubMed )
Supplement: 13045_2021_1114_MOESM2_ESM.xlsx › Sheet1
Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia.
Chang YH et al.
Scientific Reports, 2021
33436855 (PubMed )
Supplement: 41598_2020_80613_MOESM1_ESM.pdf
The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
Kampen KR et al.
Leukemia, 2019
29930300 (PubMed )
Supplement: NIHMS77878-supplement-Supplementary_information.docx
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S et al.
Leukemia, 2018
28852199 (PubMed )
Supplement: leu2017276x7.xlsx › Sheet1
Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM et al.
Oncotarget, 2016
27590521 (PubMed )
Supplement: oncotarget-07-64071-s002.xlsx › Table_S4_diagnostic_mutations
Select a paper to view details